[18F]FMISO PET in metastatic neuroendocrine tumours: a pilot study

Document Type : Original Article

Authors

1 Faculty of Medicine and Health, University of Sydney, Camperdown, Australia and Department of Medical Oncology, Royal North Shore Hospital, St Leonards, Australia

2 Faculty of Medicine and Health, University of Sydney, Camperdown, Australia

3 Department of Medical Oncology, Royal North Shore Hospital St Leonards, Sydney, NSW, 2065, Australia

4 Department of Nuclear Medicine, Royal North Shore Hospital, St Leonards, Australia

Abstract

Objective(s): The phenomenon of peripheral [68Ga]DOTATATE avidity without central avidity (which we have termed a “DONUT") has been observed in neuroendocrine neoplasm (NEN) lesions. There has been speculation as to whether this is due to hypoxia, de-differentiated disease or other causes. The presence of hypoxia may have prognostic and therapeutic implications, and was evaluated in these lesions using the PET hypoxia imaging biomarker [18F]FMISO.
Methods: Prospective pilot study in patients with metastatic NENs with at least one DONUT lesion (central [68Ga]DOTATATE non-avidity). [18F]FDG and [18F]FMISO scans were acquired within 60 days of the [68Ga]DOTATATE PET/CT. [18F]FMISO scans were acquired as a dynamic scan over 20 mins from injection with a delayed image at 2 hours. The dynamic acquisition was analysed quantitatively using a graphical approach yielding parametric images of Influx Rate Constant and Volume of Distribution. [18F]FMISO uptake within the identified DONUT hole on the 2 hr delayed scan was qualitatively scored by two experienced nuclear medicine physicians as: 0 (no uptake), 1 (uptake less than normal liver), 2 (uptake equal to normal liver), or 3 (uptake greater than normal liver).
Results: Ten patients were enrolled with primary sites including pancreas (n=3), small bowel (n=3), rectum (n=2), duodenum (n=1) and lung (n=1).  Six subjects were scored 1, three subjects were scored 2, and one subject was scored 3. All lesions evaluated were located in the liver. Quantitative [18F]FMISO parametric imaging showed evidence of increased uptake rate (Ki) in the photopenic areas of the DONUT lesions in 8/10 subjects. Surrounding uptake rate in normal liver was extremely low. In the qualitative delayed image assessment, only one subject demonstrated [18F]FMISO uptake greater than surrounding normal liver (small bowel primary, G2).
Conclusion: Only one of ten patients with DONUT lesions demonstrated increased [18F]FMISO uptake rate on delayed static imaging. In contrast, dynamic imaging demonstrated increased [18F]FMISO uptake rate in the region of [68Ga]DOTATATE photopenia on 8 of 10 patients. Future research using [18F]FMISO in NEN patients should incorporate dynamic imaging.

Keywords

Main Subjects

References

  1. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017; 3:1335–42.
  2. Hallet J, Law CHL, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population‐based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015; 121: 589–97.
  3. Brunner P, Jörg A-C, Glatz K, Bubendorf L, Radojewski P, Umlauft M, et al. The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2016; 44: 468-75.
  4. Campana D, Ambrosini V, Pezzilli R, Fanti S, Labate AMM, Santini D, et al. Standardized uptake values of 68Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine J Nucl Med. 2010; 51: 353-9.
  5. Binderup T, Knigge U, Johnbeck CB, Loft A, Berthelsen AK, Oturai P, et al. 18F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-year follow-up study. J Nucl Med. 2021; 62: 808-15.
  6. Chan DL, Hayes AR, Karfis I, Conner A, Furtado O’Mahony L, Mileva M, et al. Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score. Br J Cancer. 2023; 128: 549-55.
  7. Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia. 2015; 3: 83-92.
  8. Deschamps L, Bacha D, Rebours V, Mebarki M, Bretagnol F, Panis Y, et al. The expression of the hypoxia markers CA9 and CXCR4 is correlated with survival in patients with neuroendocrine tumours of the ileum. Neuroendocrinology. 2012; 95: 214-22.
  9. Pinato DJ, Tan TM, Toussi STK, Ramachandran R, Martin N, Meeran K, et al. An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. Br J Cancer. 2014; 110: 115-22.
  10. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013; 24: 152-60.
  11. Demir R, Pohl J, Agaimy A, Peros G, Perrakis A, Merkel S, et al. Necrosis and angioinvasion predict adverse outcome in pancreatic neuroendocrine tumors after curative surgical resection: results of a single-center series. World J Surg. 2011; 35: 2764-72.
  12. Prekeges JL, Rasey JS, Grunbaum Z, Krohn KH. Reduction of fluoromisonidazole, a new imaging agent for hypoxia. Biochem Pharmacol. 1991; 42: 2387-95.
  13. Lopes S, Ferreira S, Caetano M. PET/CT in the evaluation of hypoxia for radiotherapy planning in head and neck tumors: systematic literature review. J Nucl Med Technol. 2021; 49: 107-13.
  14. Hirata K, Yamaguchi S, Shiga T, Kuge Y, Tamaki N. The roles of hypoxia imaging using 18F-Fluoromisonidazole positron emission tomography in glioma treatment. J Clin Med. 2019; 8: 1088.
  15. Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, et al. Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017; 7: 1149-58.
  16. Tong X, Srivatsan A, Jacobson O, Wang Y, Wang Z, Yang X, et al. Monitoring tumor hypoxia using (18)F-FMISO PET and pharmacokinetics modeling after photodynamic therapy. Sci Rep. 2016; 6: 31551.
  17. Ohkubo T, Kurihara Y, Ogawa M, Nengaki N, Fujinaga M, Mori W, et al. Automated radiosynthesis of two 18F-labeled tracers containing 3-fluoro-2-hydroxypropyl moiety, [18F]FMISO and [18F]PM-PBB3, via [18F] epifluorohydrin. EJNMMI Radiopharm Chem. 2021; 6: 23.
  18. Reeves KM, Song PN, Angermeier A, Della Manna D, Li Y, Wang J, et al. 18F-FMISO PET imaging identifies hypoxia and immuno-suppressive tumor micro-environments and guides targeted evofosfamide therapy in tumors refractory to PD-1 and CTLA-4 Clin Cancer Res. 2022; 28: 327-37.
  19. Lee S, Tebbutt N, Gan HK, Liu Z, Sachinidis J, Pathmaraj K, et al. Evaluation of [18F]-FMISO PET and [18F]-FDG PET scans in assessing the therapeutic response of patients with metastatic colorectal cancer treated with anti-angiogenic therapy. Front Oncol. 2021; 11:606210.
  20. Puri T, Greenhalgh TA, Wilson JM, Franklin J, Wang LM, Strauss V, et al. [18F] Fluoromisonidazole PET in rectal cancer. EJNMMI Res. 2017; 7:78.
  21. Bailey D, Schembri G, Yeow J, Johnson M, Ghasemzadeh M, Bailey E, et al. Normal values for uptake rate constant (Ki) for [18F]-fluoroethyl-L-tyrosine (FET) in brain. J Nucl Med. 2013; 54: 13-13.
  22. Common terminology criteria for adverse events (CTCAE) Version 0. 27 November 2017.
  23. Kato Y, Yashiro M, Fuyuhiro Y, Kashiwagi S, Matsuoka J, Hirakawa T, et al. Effects of acute and chronic hypoxia on the radiosensitivity of gastric and esophageal cancer cells. Anticancer Res. 2011; 31: 3369–75.
  24. Sato J, Kitagawa Y, Yamazaki Y, Hata H, Asaka T, Miyakoshi M, et al. Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2014; 41: 2031-41.
  25. Yamaguchi S, Hirata K, Toyonaga T, Kobayashi K, Ishi Y, Motegi H, et al. Change in 18F-Fluoromisonidazole PET is an early predictor of the prognosis in the patients with recurrent high-grade glioma receiving bevacizumab treatment. PLoS One. 2016; 11: e0167917.
  26. Rajendran JG, Krohn KA. F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy. Semin Nucl Med. 2015; 45: 151-62.
  27. Eschmann S-M, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005; 46: 253-60.
  28. Thorwarth D, Eschmann S-M, Scheiderbauer J, Paulsen F, Alber M. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer. 2005; 5: 152.
  29. Grkovski M, Schöder H, Lee NY, Carlin SD, Beattie BJ, Riaz N, et al. Multiparametric imaging of tumor hypoxia and perfusion with 18F-Fluoromisonidazole dynamic PET in head and neck cancer. J Nucl Med. 2017; 58: 1072-80.
  30. Welz S, Paulsen F, Pfannenberg C, Reimold M, Reischl G, Nikolaou K, et al. Dose escalation to hypoxic subvolumes in head and neck cancer: a randomized phase II study using dynamic [18F]FMISO PET/CT. Radiother Oncol. 2022; 171: 30-6.
  31. Young K, Lawlor RT, Ragulan C, Patil Y, Mafficini A, Bersani S, et al. Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. Gut. 2021; 70: 1904-13.
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 13, Issue 2
July 2025
Pages 117-125

Files

Share

How to cite

Statistics